<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984422</url>
  </required_header>
  <id_info>
    <org_study_id>38RC19.099</org_study_id>
    <secondary_id>2019-A00987-50</secondary_id>
    <nct_id>NCT03984422</nct_id>
  </id_info>
  <brief_title>Application for Monitoring and Evaluation of Raynaud's Phenomenon</brief_title>
  <acronym>RaynaudMoni</acronym>
  <official_title>Development of an Application for the Monitoring and Evaluation of Raynaud's Phenomenon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the feasibility of using a smartphone application for monitoring and evaluation
      of Raynaud's Phenomenon.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Satisfaction assessed by a 5-points Likert scales about using the application for the monitoring and evaluation of Raynaud's Phenomenon</measure>
    <time_frame>2 weeks</time_frame>
    <description>The questionnaire assesses different items such as the ease of use of the application, the installation process on the smartphone, the use of reminders, etc. Overall satisfaction will be calculated as the non-weighted average of all items.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between cutaneous digital temperature assessed by thermography and the severity of Raynaud's Phenomenon</measure>
    <time_frame>2 weeks</time_frame>
    <description>Correlation between digital temperature and Raynaud's Condition Score (RCS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between cutaneous digital temperature assessed by thermography and the frequency of RP attacks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Correlation between digital temperature and the daily frequency of attacks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between cutaneous digital temperature assessed by thermography and the duration of RP attacks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Correlation between digital temperature and the cumulative daily duration of attacks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between cutaneous digital temperature assessed by thermography and pain during RP attacks</measure>
    <time_frame>2 weeks</time_frame>
    <description>Correlation between digital temperature and pain during attacks (assessed through a 10-point VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Raynaud etiology on thermographic data</measure>
    <time_frame>2 weeks</time_frame>
    <description>Comparison of cutaneous digital temperature between patients with primary and secondary Raynaud</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Raynaud treatment on thermographic data</measure>
    <time_frame>2 weeks</time_frame>
    <description>Comparison of cutaneous digital temperature between patients treated with calcium channel blockers and untreated patients</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Raynaud Phenomenon</condition>
  <arm_group>
    <arm_group_label>Raynaud phenomenon</arm_group_label>
    <description>Use of smartphone application</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Smartphone application</intervention_name>
    <description>use of smartphone application during 2 weeks to 3 months to collect frequency and duration of crises, RCS, photography of finger.</description>
    <arm_group_label>Raynaud phenomenon</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be selected in conjunction with a scheduled consultation in the Vascular
        Medicine Department or at the Clinical Research Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary or secondary Raynaud phenomenon clinically diagnosed by a physician

          -  Phone compatible with the application (most Android smartphones)

          -  Non-opposition of participation in the study

          -  Affiliation to the social security scheme or beneficiary of such a scheme

        Exclusion Criteria:

          -  Subject under administrative or judicial supervision

          -  Subject not speaking and not understanding French
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu Roustit, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthieu Roustit, PharmD, PhD</last_name>
    <phone>+33476767856</phone>
    <email>mroustit@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adeline PARIS, PharmD, PhD</last_name>
    <phone>+33476767383</phone>
    <email>aparis@chu-grenoble.fr</email>
  </overall_contact_backup>
  <reference>
    <citation>Wigley FM, Flavahan NA. Raynaud's Phenomenon. N Engl J Med. 2016 Aug 11;375(6):556-65. doi: 10.1056/NEJMra1507638. Review.</citation>
    <PMID>27509103</PMID>
  </reference>
  <reference>
    <citation>Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012 Aug;8(8):469-79. doi: 10.1038/nrrheum.2012.96. Epub 2012 Jul 10. Review.</citation>
    <PMID>22782008</PMID>
  </reference>
  <reference>
    <citation>Seibold JR, Wigley FM. Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames). Arthritis Rheumatol. 2017 Dec;69(12):2256-2258. doi: 10.1002/art.40307. Epub 2017 Nov 10.</citation>
    <PMID>28859256</PMID>
  </reference>
  <reference>
    <citation>Roustit M, Giai J, Gaget O, Khouri C, Mouhib M, Lotito A, Blaise S, Seinturier C, Subtil F, Paris A, Cracowski C, Imbert B, Carpentier P, Vohra S, Cracowski JL. On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: A Series of n-of-1 Trials. Ann Intern Med. 2018 Nov 20;169(10):694-703. doi: 10.7326/M18-0517. Epub 2018 Oct 30.</citation>
    <PMID>30383134</PMID>
  </reference>
  <reference>
    <citation>Fava A, Wung PK, Wigley FM, Hummers LK, Daya NR, Ghazarian SR, Boin F. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon. Arthritis Care Res (Hoboken). 2012 Jun;64(6):925-9. doi: 10.1002/acr.21622. Epub 2012 Jan 24.</citation>
    <PMID>22275160</PMID>
  </reference>
  <reference>
    <citation>Denton CP, Hachulla É, Riemekasten G, Schwarting A, Frenoux JM, Frey A, Le Brun FO, Herrick AL; Raynaud Study Investigators. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study. Arthritis Rheumatol. 2017 Dec;69(12):2370-2379. doi: 10.1002/art.40242.</citation>
    <PMID>29193819</PMID>
  </reference>
  <reference>
    <citation>Maricq HR, Carpentier PH, Weinrich MC, Keil JE, Franco A, Drouet P, Ponçot OC, Maines MV. Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol. 1993 Jan;20(1):70-6.</citation>
    <PMID>8441170</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2019</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>smartphone application</keyword>
  <keyword>monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raynaud Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

